POLARYX THERAPEUTICS, INC.

Ajouter à une liste

Communiqués Polaryx Therapeutics, Inc.

Actions

PLYX

US73110F1003

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 22/09/2026			Varia. 5j.	Varia. 1 janv.
2,150 ^USD	+0,47%		+5,13%	-

01/09	Polaryx Therapeutics, Inc. annonce la nomination du Dr Will Charlton au poste de Chief Medical Officer, effective au 1er septembre 2026	CI
25/08	Polaryx Therapeutics, Inc. progresse dans sa préparation opérationnelle pour l'essai "basket" de phase 2 SOTERIA	CI

Communiqués

01/09	Polaryx Therapeutics Appoints Dr. Will Charlton as Chief Medical Officer	AQ
25/08	Polaryx Therapeutics Advances Operational Readiness for SOTERIA Phase 2 Basket Trial	AQ
28/05	Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial	AQ
14/05	Polaryx Therapeutics Receives GHP Magazine’s Healthcare & Pharmaceuticals Awards	AQ
23/04	Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference	AQ
21/04	Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial	AQ
15/04	Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care	AQ
01/04	Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference	AQ
17/03	Polaryx Therapeutics Receives FDA Fast Track Designation for PLX‑200 for Late‑Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease)	AQ
12/03	Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events	AQ
02/03	Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders	AQ
27/02	Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders	AQ
17/02	Polaryx Therapeutics Selects Contract Research Organization for SOTERIA Phase 2 Basket Trial	AQ
10/02	Polaryx Announces Key Pre-Clinical Data Related to SOTERIA at the 22nd Annual WORLDSymposium™	AQ
05/02	Polaryx Therapeutics Welcomes New Members of the Board of Directors	AQ
03/02	Polaryx to Present Late-Breaker Data Related to SOTERIA at the 22nd Annual WORLDSymposium™ as Company Prepares for SOTERIA Trial Launch	AQ
02/02	Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol “PLYX”	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Articles Zonebourse Analyses Zonebourse

Filtres

-40% : Prolongation exceptionnelle ➤➤➤➤

PROFITEZ-EN MAINTENANT